Vistagen Therapeutics (VTGN) Set to Announce Earnings on Thursday

Vistagen Therapeutics (NASDAQ:VTGN) is scheduled to be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.30 million. Vistagen Therapeutics had a negative return on equity of 35.12% and a negative net margin of 3,421.85%. During the same period in the prior year, the company posted ($0.94) earnings per share. On average, analysts expect Vistagen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vistagen Therapeutics Price Performance

Shares of NASDAQ:VTGN opened at $3.15 on Wednesday. The company has a market cap of $85.24 million, a P/E ratio of -2.13 and a beta of 0.78. Vistagen Therapeutics has a 1 year low of $2.45 and a 1 year high of $5.86. The stock’s fifty day moving average price is $3.11 and its 200-day moving average price is $3.58.

Wall Street Analyst Weigh In

Separately, William Blair raised Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.